Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Documenti analoghi

• Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like receptor 7 agonist ruzotolimod
  di: Qiudi Jiang, et al.
  Pubblicazione: (2024)
• Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors
  di: Guihong Yang, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study
  di: Jia‐yu Zhang, et al.
  Pubblicazione: (2024)
• Correction to “Clinical pharmacokinetics of atropine oral gel formulation in healthy volunteers”
  Pubblicazione: (2024)